These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 1366088)

  • 41. Technology, medicine & health, Part 3. Therapeutics for tomorrow.
    Davidson SN
    Healthc Forum J; 1995; 38(1):52-60. PubMed ID: 10154288
    [No Abstract]   [Full Text] [Related]  

  • 42. [Gene technology and current possibilities for pharmacological intervention].
    Pelkonen O
    Duodecim; 1992; 108(15):1299-300. PubMed ID: 1366088
    [No Abstract]   [Full Text] [Related]  

  • 43. [Therapeutic applications of genetic engineering].
    Descamps JL
    Ann Pharm Fr; 1994; 52(6):294-302. PubMed ID: 7864529
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Antisense oligonucleotides: a new therapeutic approach].
    Guinot P; Temsamani J
    Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Engineered riboswitches as novel tools in molecular biology.
    Bauer G; Suess B
    J Biotechnol; 2006 Jun; 124(1):4-11. PubMed ID: 16442180
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antisense oligonucleotide technology in the development of cancer therapeutics.
    Tseng BY; Brown KD
    Cancer Gene Ther; 1994 Mar; 1(1):65-71. PubMed ID: 7621240
    [No Abstract]   [Full Text] [Related]  

  • 48. Antisense technology: commercial implications.
    Hawkins JW
    Antisense Res Dev; 1991; 1(3):283-4. PubMed ID: 1821649
    [No Abstract]   [Full Text] [Related]  

  • 49. Antisense oligonucleotides for haematological malignancies.
    Cotter FE
    Haematologica; 1999 Jun; 84 Suppl EHA-4():19-22. PubMed ID: 10907458
    [No Abstract]   [Full Text] [Related]  

  • 50. Application of antisense oligonucleotides for gene functionalization and target validation.
    Bennett CF; Cowsert LM
    Curr Opin Mol Ther; 1999 Jun; 1(3):359-71. PubMed ID: 11713801
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gene therapy in hematology.
    Benz EJ; Bank A
    Rev Invest Clin; 1994 Apr; Suppl():143-6. PubMed ID: 7886298
    [No Abstract]   [Full Text] [Related]  

  • 52. Antisense oligonucleotide technology: from EST to therapeutics.
    Giles RV
    Curr Opin Mol Ther; 2000 Jun; 2(3):238-52. PubMed ID: 11249617
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.